AbbVie Acquisition +4.5%: AbbVie Bets Big on Apogee

Is AbbVie’s $10.9 billion Apogee deal a bold immunology masterstroke, or an expensive bet on future growth? Maik Kemper Editor in Chief The acquisition of Apogee further builds…